Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 5, 2008, Pages 498-505

  Nobre, Vandack ^a   Harbarth, Stephan ^a   Graf, Jean Daniel ^a   Rohner, Peter ^a,b   Pugin, Jérôme ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Antibiotics; Controlled tria; Intensive care; Procalcitonin; Sepsis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; MACROLIDE; PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN; GLYCOPROTEIN; PROTEIN PRECURSOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; ALGORITHM; BLOOD; CLINICAL PROTOCOL; CRITICAL ILLNESS; KAPLAN MEIER METHOD; LENGTH OF STAY; MIDDLE AGED; MORTALITY; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-BACTERIAL AGENTS; CALCITONIN; CLINICAL PROTOCOLS; CRITICAL ILLNESS; FEMALE; GLYCOPROTEINS; HUMANS; KAPLAN-MEIERS ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RECURRENCE; SEPSIS; SHOCK, SEPTIC;

EID: 40649087642     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200708-1238OC     Document Type: Article

References (30)

1. Calandra T, Cohen J. The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-1548.
2. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-490.
3. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, et al. Cost of gram-negative resistance. Crit Care Med 2007;35:89-95.
4. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87-93.
5. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598.
6. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-518.
7. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-217.
9. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-607.
10. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
11. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-2602.
12. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.
13. Muller B, Christ-Crain M, Schuetz P. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007;7:498-499.
14. Reinhart K, Brunkhorst FM. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007;7:500-502.
15. Nobre V, Harbarth S, Graf J-D, Rohner P, Pugin J. Procalcitonin guidance allows shortening antibiotic treatment duration in patients with severe sepsis and septic shock: results of a randomized clinical trial [abstract L-613]. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy meeting, Chicago, IL; September 17, 2007.
16. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1483.
17. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
18. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, Le Gall JR. SAPS 3: from evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description. Intensive Care Med 2005;31:1336-1344.
19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG, for the Working group on Sepsisrelated Problems of the European Society of Intensive Care Medicine. The SOFA(Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710.
20. Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003;36:823-824. [Author reply, 826-827.]
21. Harbarth S, Viot M, Beeler I, Klastersky J, Szucs T. Variation in antimicrobial utilization for febrile neutropenia in cancer patients. The CEMIC study group (Club d'Etudes des Maladies Infectieuses en Cancer). Infection 2000;28:375-378.
22. Hugonnet S, Eggimann P, Sax H, Touveneau S, Chevrolet JC, Pittet D. Intensive care unit-acquired infections: is postdischarge surveillance useful? Crit Care Med 2002;30:2636-2638.
23. Eggimann P, Hugonnet S, Sax H, Harbarth S, Chevrolet JC, Pittet D. Long-term reduction of vascular access-associated bloodstream infection. Ann Intern Med 2005;142:875-876.
24. Harbarth S. Nosocomial transmission of antibiotic-resistant microorganisms. Curr Opin Infect Dis 2001;14:437-442.
25. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJ, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355.
26. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006;22:503-519.
27. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996-2003.
28. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19.
29. Harbarth S. [The effect of antimicrobial use on emergence and selection of resistance.] Anasthesiol Intensivmed Notfallmed Schmerzther 2007;42:130-135. In German.
30. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004;32:625-631.